Researchers have successfully eradicated HIV from cells in a laboratory setting using the gene-editing tool Crispr-Cas, which was awarded the Nobel Prize in 2020. By targeting HIV DNA, scientists effectively removed all traces of the virus from infected cells.
Functioning akin to molecular scissors, Crispr-Cas technology can precisely cut DNA at specific points, allowing for the removal of undesirable genes or the introduction of new genetic material into cells.
The objective of the study authors was to develop a robust and safe Crispr-Cas protocol, to achieve a universally accessible HIV cure capable of deactivating diverse HIV strains across various cellular environments. Dr Elena Herrera-Carrillo and her team spearheaded this effort, including Yuanling Bao, Zhenghao Yu, and Pascal Kroon from Amsterdam UMC in the Netherlands.
Their research led to the creation of an effective method to combat the virus in different types of cells and locations where it might be concealed. The team described their findings as a significant step forward in designing a cure strategy for HIV.
Given that HIV can infect various cells and tissues throughout the body, the researchers sought to develop a method to target the virus wherever it resides. Their study, presented at the European Congress of Clinical Microbiology and Infectious Diseases, focused on identifying conserved regions of the virus present across all known strains. This approach aimed to establish a broad-spectrum therapy capable of addressing multiple HIV variants effectively.
However, the researchers emphasized that while their work represents a proof of concept, it does not signify an immediate cure for HIV. They outlined the need for further optimization of delivery methods to target the majority of HIV reservoir cells. Their ultimate goal is to develop a safe and efficient strategy for clinical application, striking the right balance between efficacy and safety.
The researchers cautioned against premature declarations of a functional HIV cure, emphasizing the necessity for rigorous clinical trials to assess the feasibility and safety of this approach in humans. Despite the promising nature of their preliminary findings, they underscored the importance of continued research and development before a viable cure for HIV can be realized.
Seunmanuel Faleye is a brand and communications strategist. He is a covert writer and an overt creative head. He publishes Apple’s Bite International Magazine.
